Abstract

<div>Abstract<p><b>Purpose:</b> The objective of this study was to identify genetic polymorphisms related to the pharmacokinetics and pharmacodynamics of sunitinib that are associated with a prolonged progression-free survival (PFS) and/or overall survival (OS) in patients with clear-cell metastatic renal cell cancer (mRCC) treated with sunitinib.</p><p><b>Experimental design:</b> A retrospective multicenter pharmacogenetic association study was performed in 136 clear-cell mRCC patients treated with sunitinib. A total of 30 polymorphisms in 11 candidate genes, together with clinical characteristics were tested univariately for association with PFS as primary and OS as secondary outcome. Candidate variables with <i>P</i> < 0.1 were analyzed in a multivariate Cox regression model.</p><p><b>Results:</b> Multivariate analysis showed that PFS was significantly improved when an A-allele was present in <i>CYP3A5</i> 6986A/G [hazard ratio (HR), 0.27; <i>P</i> = 0.032], a CAT copy was absent in the <i>NR1I3</i> haplotype (5719C/T, 7738A/C, 7837T/G; HR, 1.76; <i>P</i> = 0.017) and a TCG copy was present in the <i>ABCB1</i> haplotype (3435C/T, 1236C/T, 2677G/T; HR, 0.52; <i>P</i> = 0.033). Carriers with a favorable genetic profile (n = 95) had an improved PFS and OS as compared with noncarriers (median PFS and OS: 13.1 versus 7.5 months and 19.9 versus 12.3 months). Next to the genetic variants, the Memorial Sloan-Kettering Cancer Center prognostic criteria were associated with PFS and OS (HR, 1.99 and 2.27; <i>P</i> < 0.001).</p><p><b>Conclusions:</b> This exploratory study shows that genetic polymorphisms in three genes involved in sunitinib pharmacokinetics are associated with PFS in mRCC patients treated with this drug. These findings advocate prospective validation and further elucidation of these genetic determinants in relation to sunitinib exposure and efficacy. <i>Clin Cancer Res; 17(3); 620–9. ©2010 AACR</i>.</p></div>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.